ViGeneron in Munich, Germany has launched a new Phase 1b clinical trial testing a novel gene replacement therapy in individuals affected by retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This new therapy can be injected into the vitreous. Injections such as these are frequently done in an ophthalmologist’s office and do not require more advanced surgery. Read More